Uwe Christians, M.D., is editor-in-chief of Therapeutic Drug Monitoring, the Official Journal of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), which was founded by C.E. Pippenger in 1979.
Christians received his M.D. (with highest honors) and his Ph.D. in Experimental, Clinical Pharmacology and Toxicology from the Medizinische Hochschule Hannover in Hannover, Germany, where he is a board certified pharmacologist, toxicologist and clinical pharmacologist. He is board certified by the American Board of Clinical Pharmacologists.
Christians also is the laboratory director of the Department of Anesthesiology’s iC42 Clinical Research and Development laboratory located in Bioscience 2, a global resource for “high-end” and regulatory compliant bioanalytics that currently collaborates with more than 50 entities including academic groups, clinical networks, biotech and pharmaceutical companies all over the world.
Therapeutic Drug Monitoring is a peer-reviewed, multidisciplinary journal. IATDMCT defines therapeutic drug monitoring as a multi-disciplinary clinical specialty aimed at improving patient care by individually adjusting the dose of drugs for which clinical experience or clinical trials have shown it improves outcomes in the general or special populations. Individually adjusted dosing can be based on a priori pharmacogenetic, demographic and clinical information, and/or on the a posteriori measurement of drug concentrations (pharmacokinetic monitoring) and/or biomarkers (pharmacodynamic monitoring).
The scope, goals and objectives of Therapeutic Drug Monitoring reflect IATDMCT’s definition of therapeutic drug monitoring whereas, Therapeutic Drug Monitoring is the journal of “Personalized Drug Therapy and Clinical Toxicology” and publishes original articles, short communications, review articles and grand rounds articles that advance the field and educate pharmacist, biomedical scientists, toxicologists, and clinicians. Accordingly, manuscripts describing clinical studies, pharmacogenomics studies, method development and validations, biomarker discovery, development and validation, pharmacokinetic/ pharmacodynamics modeling, population pharmacokeintics and basic research with a direct relevance to personalized drug therapy of patients will be considered for publication in Therapeutic Drug Monitoring.
High-quality submissions within the scope of the journal from researchers on campus are welcome. Email: firstname.lastname@example.org